112 related articles for article (PubMed ID: 18343750)
1. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function.
Alvarez-Lerma F; Allepuz-Palau A; Garcia MP; Angeles Leon M; Navarro A; Sanchez-Ruiz H; Iruretagoyena JR; Luque-Gomez P;
J Chemother; 2008 Feb; 20(1):93-100. PubMed ID: 18343750
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
von Mach MA; Burhenne J; Weilemann LS
BMC Clin Pharmacol; 2006 Sep; 6():6. PubMed ID: 16981986
[TBL] [Abstract][Full Text] [Related]
3. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
4. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
5. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
6. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients.
Alvarez-Lerma F; Nicolás-Arfelis JM; Rodríguez-Borregán JC; Díaz-Regañón J; Sa-Borges M; García-López F; Allepuz-Palau A
J Chemother; 2005 Aug; 17(4):417-27. PubMed ID: 16167522
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of intravenous voriconazole in patients with compromised renal function.
Lilly CM; Welch VL; Mayer T; Ranauro P; Meisner J; Luke DR
BMC Infect Dis; 2013 Jan; 13():14. PubMed ID: 23320795
[TBL] [Abstract][Full Text] [Related]
9. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.
Kim SH; Kwon JC; Park C; Han S; Yim DS; Choi JK; Cho SY; Lee HJ; Park SH; Choi SM; Choi JH; Yoo JH; Lee DG; Lee JW
Mycoses; 2016 Oct; 59(10):644-51. PubMed ID: 27324913
[TBL] [Abstract][Full Text] [Related]
11. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis.
Burkhardt O; Thon S; Burhenne J; Welte T; Kielstein JT
Int J Antimicrob Agents; 2010 Jul; 36(1):93-4. PubMed ID: 20381320
[No Abstract] [Full Text] [Related]
12. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
[TBL] [Abstract][Full Text] [Related]
13. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.
Oude Lashof AM; Sobel JD; Ruhnke M; Pappas PG; Viscoli C; Schlamm HT; Rex JH; Kullberg BJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3133-7. PubMed ID: 22450974
[TBL] [Abstract][Full Text] [Related]
15. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.
Fuhrmann V; Schenk P; Jaeger W; Miksits M; Kneidinger N; Warszawska J; Holzinger U; Kitzberger R; Thalhammer F
J Antimicrob Chemother; 2007 Nov; 60(5):1085-90. PubMed ID: 17855725
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.
Hafner V; Czock D; Burhenne J; Riedel KD; Bommer J; Mikus G; Machleidt C; Weinreich T; Haefeli WE
Antimicrob Agents Chemother; 2010 Jun; 54(6):2596-602. PubMed ID: 20368400
[TBL] [Abstract][Full Text] [Related]
18. Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients.
Eichhorn ME; Wolf H; Küchenhoff H; Joka M; Jauch KW; Hartl WH
Eur J Clin Microbiol Infect Dis; 2007 Jun; 26(6):395-402. PubMed ID: 17530306
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
Heinz WJ; Egerer G; Lellek H; Boehme A; Greiner J
Mycoses; 2013 May; 56(3):304-10. PubMed ID: 23170837
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
